A Review of the Extent of HIV Drug Resistance in Vietnam

Quang D. Pham1,2, David P. Wilson1 and Lei Zhang1*
1The Kirby Institute, University of New South Wales, Sydney, Australia
2Pasteur Institute, Ho Chi Minh City, Vietnam

Abstract

Background: In 2005, free antiretroviral therapy (ART) was rolled-out as a national program in Viet Nam. The estimated population of people living with HIV reached 254,000 in 2010 and this leads to increasing demand of ART in the near future. By 2009, ART coverage reached 53.7% for adults and adolescents, and 49.7% for children. This study aims to describe the prevalence of HIV acquired drug resistance (ADR) among people receiving ART and prevalence of transmitted drug resistance (TDR) among recently HIV-infected persons in Vietnam, and their associated ART coverage, antiretroviral treatment adherence and risk behaviors.

Methods: We performed a comprehensive review of published English literature containing relevant epidemiological and behavioral indicators through internet searches.

Results: Twenty-one relevant publications were included in this review. TDR prevalence among people recently infected with HIV increased from below 5% in 2006 to a higher level of 5-15% during 2007-2008 in urban Vietnam, whereas TDR prevalence among chronic antiretroviral-naïve HIV-infected adults stabilized between 6-8% across the country. About half of all adults and children with clinical or immunological criteria of therapeutic failure had evidence of developing resistance to antiretroviral drugs. Non-adherence among adults on ART ranged between 25-32% and the level of viral suppression (< 1,000 copies/ml) fluctuated from 68% to more than 83% at 12 month after initiating ART. However, relevant data concerning children were mostly absent.

Conclusion: Increasing trend of transmission of HIV drug resistance was observed in urban Vietnam, suggesting an urgency of the establishment of regular surveillance for TDR. Viral load testing and availability of second or third line ART are recommended for the early diagnosis of drug resistance and prevention of its accumulation and transmission.

Keywords: Review; HIV; Drug resistance; Vietnam

Introduction

The Vietnam’s HIV epidemic remains concentrated among high-risk populations since the first case reported in late 1990. The overall HIV prevalence was estimated to be 0.44% among people aged between 15-49 years in 2010 [1]. In comparison, much higher prevalence was observed among drug users (IDU) (18.4% in 2009), female sex worker (FSW, 3.2% in 2009) since the establishment of the national HIV sentinel surveillance in 1994 [2]. However, the latest data indicated a remarkable increase of HIV prevalence among men who have sex with men (MSM, 16.7% in 2009 [2]). The estimated population of people living with HIV (PLHIV) more than doubled during the past decade, reaching approximately 254,000 in 2010 [1,2]. This is expected to lead to a high demand of antiretroviral (ARV) treatment in the near future.

Antiretroviral therapy (ART) can substantially slow AIDS disease progression and reduce morbidity and mortality among HIV-infected populations [3-5]. However, under ARV drugs pressure, people receiving ART develop drug-resistant strains of HIV, namely, acquired drug resistance (ADR). These strains can be transmitted through exchange of body fluids, and susceptible individuals are then infected with the transmitted drug resistant strains of HIV (TDR). Many developed countries, with a long history of ART implementation, reported high prevalence of both ADR and TDR, typically ranged between 35-60% [6,7] and 8-25% [8-18], respectively. Recently, several developing countries also reported increasing transmission of HIV drug resistance [19-21], despite that the overall prevalence of TDR remained low. Although ART through public out-patient clinics has been available in Vietnam for nearly ten years, it was not until 2005 Vietnam received sufficient support from the United States President’s Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis, and Malaria to roll-out its free ART programs on a national level. Since then, several regional surveys reported the prevalence of HIV resistance across various populations, adherence to ART, and risk behaviors of PLHIV, revealing the emergence and transmission of HIV drug resistance. However, to our best knowledge, no review on HIV drug resistance in relation to ARV treatment in Vietnam has been published.

This review aims to describe the epidemic of the emerging drug resistant strains of HIV among people receiving ART and its transmission among recently infected individuals in Vietnam. We further estimate the coverage of ART among treatment-eligible population in both adults and children populations, and describe treatment adherence and risk behaviors among people receiving ART. The results of our study may provide an overview of HIV drug resistance in this country, determine current knowledge gaps in understanding of the transmission pattern, and recommend suitable intervention strategies for minimizing the emergence and spread of HIV drug resistance in Vietnam.
Methods

We estimate ART coverage in Vietnam based on the available data from governmental sources. The coverage of ART among PLHIV with age over 15 years was calculated by dividing the annually reported numbers of people receiving ART by the estimated number of treatment-eligible adults and adolescents (aged 15+ years, CD4 < 200 cell/mm^3) at the same year [22]. According to the World Health Organization (WHO), HIV-infected infants or children (aged 0-14 year) should be treated with ART as soon as possible after HIV-diagnosis regardless of CD4 levels or identified WHO clinical stages [23]. Hence, we divide the number of children receiving ART by the estimated population size of HIV-infected children to estimate the coverage of ART for this population. Data was collected from two reliable reports of the Vietnam Administration of HIV/AIDS Control (VAAC), Ministry of Health [1,24]. The number of adults and adolescents receiving ART by years was made publicly available at a national HIV/AIDS conference in 2010 [1], whereas a VAAC report provided the yearly estimated number of people aged over 15 years in need of ART and number of HIV-infected children [24].

Data on the ADR prevalence, level of treatment adherence and risk behaviors among people on ART, and TDR prevalence among recently HIV-infected persons were drawn from published English literature. We performed searches in October 2011 for papers on PubMed and peer-reviewed abstracts on major international conferences (International AIDS Conference, Conference on HIV Pathogenesis and Treatment - IAS, and Conference on Retroviruses and Opportunistic Infection - CROI), according to the following search terms: (‘HIV’) AND (‘antiretroviral’ OR ‘ARV’ OR ‘ART’ OR ‘HAART’) OR (‘HIV treatment’ OR ‘HIV care’) AND (‘Vietnam’). Our review excluded studies prior to January 1, 2000 or those with sample size less than 30. A publication is included if it reported any of the prevalence of ADR, treatment adherence level or risk behaviors among people receiving ART or the prevalence of TDR among those who recently acquired HIV. Most studies investigating HIV drug resistance in Vietnam conducted a sequencing test for the specimen when its viral load level was greater than 1,000 copies/ml [25-29] and only reported the prevalence of ADR among people with a successful sequencing. However, Lee et al. [30] argued that people receiving ART with viremia less than 1,000 copies per ml is not typically associated with development of HIV drug resistance. Thus, we assume that people treated with ART who have viral load levels under this threshold harbor only wild-type HIV; this may not always be true and therefore our estimates are conservative. The prevalence of ADR is then estimated by the number of people harboring drug resistant HIV divided by number of the ART recipients having viral load testing in each published survey.

Results

The current paper reviewed twenty-one publications reporting relevant drug-resistance information including ART coverage, treatment-adherence rate and level of viral suppression during treatment, and prevalence of ADR and TDR. Of these, nineteen papers contained empirical survey data from HIV-infected populations recruited from nine Vietnamese provinces (Figure 1).

Scale-up of free ART program in Vietnam

By the end of 2004, over 21,000 HIV-infected adults and adolescents (age 15+ years) were estimated to require ART, with only approximately 500 receiving it, representing an extremely low coverage of 2.1% (range: 1.6-3.1%). The provision of ART through public sector increased nationally since 2005 when international efforts scaled-up funding for care and treatment program in Vietnam in response to the new ARV treatment guidelines at this time. Nearly 2,700 people aged over 15 years were on ART by the end 2005. This figure dramatically scaled up to over 15,000 and 36,000 by 2007 and 2009, respectively. This corresponds to an increase of ART coverage from 8.5% (range: 6.5-12.4%) in 2005 to 32.1% (range: 24.7-45.9%) in 2007 and 53.7% (range: 42.8-75.0%) in 2009. Comparably, ART coverage among HIV-infected eligible children (0-14 years) increases in a similar rate, from 15.7% (range: 15.0-16.4%) in 2005 to 39% (range: 36.0-41.2%) in 2007 and 49.7% (range: 47.6-52.0%) in 2009 (Table 1).

Prevalence of transmitted and acquired drug resistance of HIV

In accordance to the WHO’s guidelines for TDR surveillance [31], proxy recent HIV-infected populations that are ARV-naive, such as pregnant women or attendees of voluntary counselling and testing (VCT) were monitored for TDR prevalence in Vietnam. In Ho Chi Minh City (HCMC) in 2005, one of 163 (0.6%) HIV-infected pregnant women accessing prevention of mother-to-child transmission program were diagnosed with mutations associated with resistance to nucleoside reverse transcriptase inhibitor (NRTI) [32]. Further study in this city in 2006 revealed a higher prevalence of 3.2% among VCT attendees (age < 25 years and CD4 count > 500 cells/mm^3), of whom two were found be infected with HIV drug resistant mutation: one resisted non-nucleoside reverse transcriptase inhibitor (NNRTI) and the other had resistance to protease inhibitor (PI) [33]. Consistently, in 2006, among 49 adults aged 18-24 years seeking their first HIV test at VCT in Hanoi, only one person had HIV mutations, that resists both NRTI and NNRTI indicating a low TDR prevalence (< 5%) [34]. A subsequent survey in HCMC in 2007-2008 showed that up to 5% to 15% of VCT attendees aged less than 25 years developed drug resistant strains of HIV [35]. In this survey, the authors reported numerous mutations associated with
Five provinces were enrolled: Ha Noi, Hai Phong, Da Nang, Khanh Hoa, and Can Tho. Three provinces were enrolled: Ha Noi, Ninh Binh, and Nam Dinh.

15% (high).

Survey used the World Health Organization’s methodology for surveillance for transmitted HIV drug resistance with three thresholds: <5% (low), 5-15% (moderate), 15% (high).

95% CI was estimated from number of people harbouring drug resistance of HIV and number of specimen with successful genotyping with both RT and PR genes.

Baseline data of a longitudinal study.

* Median or mean age (years).

†† Baseline data of a longitudinal study.

ART, antiretroviral therapy.

Source: Presentation of Vietnam Administration for HIV/AIDS Control (VAAC), Ministry of Health: “Preliminary Results of the National Evaluation of Clinical and Immunological Response to ARV of Adult Patients in Vietnam”, Ha Noi, Vietnam 2010 (24).

Source: Vietnam HIV/AIDS Estimates and Projections, 2007 – 2012, VAAC, Ministry of Health (1).

Number of HIV-infected adults and adolescents with CD4 count less than 200 cells/mm².

Number of HIV-infected children.

Number of HIV-infected people who were ARV-naïve reported HIV mutations less than 2% throughout the same period.

Notably, resistance prevalence to PI was found higher than other drug classes, ranging between 1.1-4.5% in 2001-2007 and 4.8-6.5% in 2008-2009. Among ARV drug classes, resistance to NRTI was more common than other drug classes, ranging between 1.1-4.5% in 2001-2007 and 4.8-6.5% in 2008-2009. Notably, resistance prevalence to PI was found less than 2% throughout the same period.

Ten out of eleven surveys recruiting recently and chronically HIV-infected people who were ARV-naïve reported HIV mutations.
resistant against specific ARV drug classes. Among NRTI-mutations, those appearing in highest frequency, of five studies, were M184I/V and thymidine-analogue mutations (TAM), including M41L, D67N, K70R, L210W, and K219E/Q. Subsequently, L74I/V was documented in four surveys. Regarding other drug classes, the three most commonly observed NNRTI-mutations were Y181C (6 studies), K103N (5 studies), and G190A/S (5 studies). Mutations M46I/I (3 studies) was more commonly observed than other PI-mutation patterns (Table 2).

As shown in Table 3, most relevant studies were conducted in treatment sites in HCMC. Between 2007 and 2009, ADR prevalence among people failing multiple lines of ART was similar across study population in HCMC, ranging from 49% to 55% in adults and 50% in children (aged 0-14 years) [25-29]. In this population, resistance to NNRTI and NNRTI were documented to vary in wide ranges of 47-87% and 37-78%, respectively, and were more frequently observed than resistance to PI (< 5%). Of note, the proportion of ARV-resistant mutations was 33-35% for any TAM, 32-48% for M184I/V, whereas K65R and Q151M mutations were rarely found even among ART-failed persons (< 10% for both). Among NNRTI-mutations, K103N, Y181C/I/V, G190A/S, and Y188L were mostly observed in these studies. In contrast to high level of resistance among subjects failing with ART, a study in five northern and southern Vietnamese provinces in 2009 indicated that people on ART had a markedly lower level of adherence [43,44] (Table 4).

As shown in Table 3, most relevant studies were conducted in treatment sites in HCMC. Between 2007 and 2009, ADR prevalence among people failing multiple lines of ART was similar across study population in HCMC, ranging from 49% to 55% in adults and 50% in children (aged 0-14 years) [25-29]. In this population, resistance to NNRTI and NNRTI were documented to vary in wide ranges of 47-87% and 37-78%, respectively, and were more frequently observed than resistance to PI (< 5%). Of note, the proportion of ARV-resistant mutations was 33-35% for any TAM, 32-48% for M184I/V, whereas K65R and Q151M mutations were rarely found even among ART-failed persons (< 10% for both). Among NNRTI-mutations, K103N, Y181C/I/V, G190A/S, and Y188L were mostly observed in these studies. In contrast to high level of resistance among subjects failing with ART, a study in five northern and southern Vietnamese provinces in 2009 indicated that people on ART had a markedly lower level of adherence [43,44] (Table 4).

**Table 3:** The prevalence of acquired HIVDR and selected HIV resistant mutations among people on ART and with suspect of treatment failure in Vietnam, 2000-2009

| Characteristics | Tang et al* (42) (N=100) | Trinh et al † (44) (N=288) | Quang et al † (36) (N=140) | Do et al † (43) (N=615) |
|-----------------|--------------------------|-----------------------------|---------------------------|------------------------|
| Sample year     | 2006-2008                | 2009                        | 2008-2009                 | 2010                   |
| Location        | Ha Noi                   | HCMC                        | HCMC                      | Five rural and urban clinics |
| Poor-adherence of antiretroviral drugs, n/N (%) | 6 month: 21/81(25) | 12 month: 24/75 (32) (Self-reported with VAS) | 59/228 (25) (Self-reported) | NR |
|                 | 153/615 (25)             | (ACASI with VAS)            |                          | 153/615 (25)           |
| Viral suppression, n/N (%) | 8 month: 60/70 (74) | 12 month: 51/75 (68) (< 1,000 copies/ml) | 175/228 (77) (150,000 copies/ml) | 6 month: NR (75.6) 12 month: NR (83.1) (< 250 copies/ml) |
|                  | 59/228 (25)              | (Self-reported)             |                          | NR                     |

N, number of participants; n, frequency; HCMC, Ho Chi Minh City; ART, antiretroviral therapy; NR, not reported; VAS, a 30-day visual analogue scale for evaluating the usage of a prescribed regimen in the preceding month; ACASI, audio computer assisted self-interview.

* Adults and children with clinical or immunological criteria of first-and second-line ART failure. Abbreviations: ACASI, audio computer assisted self-interview; TAMs is thymidine-analogue mutations, including M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E.

**Table 4:** Summary of antiretroviral-adherent level and viral suppression among people on first-line ART in Vietnam, 2000-2009

| Characteristics | Tang et al* (42) (N=100) | Trinh et al† (44) (N=288) | Quang et al† (36) (N=140) | Do et al† (43) (N=615) |
|-----------------|--------------------------|-----------------------------|---------------------------|------------------------|
| Sample year     | 2006-2008                | 2009                        | 2008-2009                 | 2010                   |
| Location        | Ha Noi                   | HCMC                        | HCMC                      | Five rural and urban clinics |
| Poor-adherence of antiretroviral drugs, n/N (%) | 6 month: 21/81(25) | 12 month: 24/75 (32) (Self-reported with VAS) | 59/228 (25) (Self-reported) | NR |
|                 | 153/615 (25)             | (ACASI with VAS)            |                          | 153/615 (25)           |
| Viral suppression, n/N (%) | 8 month: 60/70 (74) | 12 month: 51/75 (68) (< 1,000 copies/ml) | 175/228 (77) (150,000 copies/ml) | 6 month: NR (75.6) 12 month: NR (83.1) (< 250 copies/ml) |
|                  | 59/228 (25)              | (Self-reported)             |                          | NR                     |

N, number of participants; n, frequency; HCMC, Ho Chi Minh City; ART, antiretroviral therapy; NR, not reported; VAS, a 30-day visual analogue scale for evaluating the usage of a prescribed regimen in the preceding month; ACASI, audio computer assisted self-interview.

* Adults and children with clinical or immunological criteria of first-and second-line ART failure. Abbreviations: ACASI, audio computer assisted self-interview; TAMs is thymidine-analogue mutations, including M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E.

**Results**

Several studies investigated adherence among adults (aged over 18 years) receiving ART in Vietnam and showed that around one quarter of adults surveyed had poor adherence to HIV medications in the preceding month. During 2006-2008 in Ha Noi, this rate among 100 HIV-acquired IDU after 6 and 12 month of initiation of ART was 26% and 32%, respectively, based on a 30-day visual analogue scale [42]. Although with different the study site, time and methodology, two other cross-sectional, clinic-based surveys in 2009-2010 also demonstrated a similar percentage of 25% self-reporting as non-adherence [43,44] (Table 4).

Only three studies have presented the virological outcome
among adult receiving ART in Vietnam (Table 4). The proportion of
viral suppression (< 1,000 copies/ml) at 6 and 12 month since ART
initiation among IDU who were recruited from a treatment site in Ha
Noi in 2006-2008, was of 74% and 68%, respectively [42]. This figure
was likely to be substantially lower than that of an average people
receiving ART. An analysis of 228 people on ART over 1 year in HCMC
indicated that 77% had a viral suppression [10], and more recently
published data in HCMC indicates a 77% and 83% rate of undetectable
viral load (< 250 copies/ml) at the first 6 and 12 months of ART [45].
No studies have ever been conducted on adherence of ART medication
and virological outcome among children receiving ART in Vietnam.
Sexual risk behaviors and illicit drug use among adults on ART were
also not found in available literature.

Discussion

There is limited information about the emergence of HIV drug
resistance in Vietnam. No longitudinal data related to the development
of ADR has been published. The available ADR prevalence was
estimated through several cross-sectional, clinic-based surveys among
people who are currently on ART or have failed first-line ART. We
assumed that people with viral load less than 1,000 copies/ml would
not have drug-resistant mutations; however, it is important to note it
is possible for these viral strains to exist in such conditions [46,47].
Therefore, our estimate of the extent of drug resistance in Vietnam is a
conservative under-estimate of the actual level. Despite this limitation,
we determined that HIV drug-resistant mutations existed in nearly
half of the ARV-treated population suspected of certain clinical and/
or immunological criteria of treatment failure. The current review also
indicates that approximately 25% of Vietnamese adults receiving ART
were classified as non-adherent, a key risk factor for the acquisition of
HIV drug resistance [48-53]. Non-adherence is caused by numerous
factors. Most adults on ART were IDU (62%) [24], whose high level of
active illicit drug use during therapy (30-33%) [42], directly impacts on
their adherence to ARV drugs. Furthermore, widespread stigma and
discrimination related to HIV infection leads to a fear of disclosure of
their HIV positive status and use of ART [54]. Addressing these issues
is complex but important for the health and well-being of all people
affected with HIV. It is also likely that most people using a failed ART
regimen would be using it for considerable time after the emergence of
drug resistant mutations. Regular viral load testing and increasing
the availabilities of therapeutic options should be considered as an
appropriate strategy to curb the emergence and transmission of HIV
drug resistance. Phillips et al. [55] showed that the introduction of
viral load monitoring leads to lower prevalence of TDR among recent
infections as well as reduced mortality among people on ART. It has
also been estimated that if viral load tests are conducted in every second
year, it would have an impact of reducing new TDR cases by more than
50% [56].

We found that ARV-resistant strains are spreading among various
adult HIV-infected populations in Vietnam. The prevalence of TDR
among proxy primary HIV-infected persons in HCMC increased
from less than 5% before 2006 to a higher level of 5-15% in 2007-2008.
This is comparable to findings from multiple cross-sectional TDR
surveys in Thailand, where prevalence gradually increased beyond the
threshold of 5% after 5 years of their ART program which commenced
in 2002 (0% in 2003, 1.2% in 2004, 2.6% in 2005, and 5.2% in 2006)
[19]. Our results suggest that the transmission of HIV drug resistance is
increasing in urban areas in Vietnam, as a result of rapid scale-up
of ART [57,58]. Therefore, surveillance for TDR should be regularly
conducted and also expanded to urban areas with high coverage of ART
[59]. In this review, several studies across the country at different time
periods further documented a similar 6-8% level of drug-resistant HIV
among chronic infections. This percentage is considerably higher than
that among HIV-infected individuals in a Chinese nationwide survey
in 2004, in which the TDR prevalence was documented as 3.8% [60].
It is generally accepted that people with TDR are more likely to have
higher rates of treatment failure during the first 12 months of treatment
if their mutation resists at least one drug in their prescribed ARV
regimens [61,62]. Based on these findings, we recommend a gradual
scale-up in procurement of second- and third-line ART to treat the
expanding population infected with TDR strains who may have failed
the standard first-line ART.

Although ART services for children have been scaled up in
Vietnam, little is known about the level of HIV drug resistance among
children on ART in Vietnam. The rate of transmission from mother
to child is as high as 14.7% in southern provinces of Vietnam [63] and
45.5% of mothers treated with dual ART for preventing transmission
to their children had the M184V mutation at delivery [32]. Hence,
mother-to-child transmission of drug-resistant strains of HIV may be
common in Vietnam.

Our review has a number of limitations. Firstly, most studies had
small sample sizes, and conveniently selected a limited number of
local sites, mostly in urban areas. This could introduce selection bias
if large heterogeneities exist across the target population. Secondly, the
majority of TDR surveys enrolled chronically HIV-infected persons
who were ARV-naïve to estimate the TDR prevalence. This approach
can underestimate the true prevalence as drug-resistant strains are
more likely to revert to wild-type after 12 months of infection
[64,65] and stay as minority-resistant strains (< 25%), which cannot
be detected by standard polymerase chain reaction [66]. Thirdly, data
may not be representative for HIV drug resistance among all people
on ART in Vietnam. Most studies in the current review estimate ADR
prevalence by enrolling individuals who have already experienced
clinical or immunological failure of ART. These persons were more
likely to harbor resistant viruses leading to an over-estimating of the
actual ADR prevalence. Lastly, due to the limited available data on HIV
medication adherence and risk behaviours, we could not completely
describe risk factors and their association with the dynamics of drug-
resistant HIV epidemics. Further studies are required to fill these gaps.

Transmission of HIV drug resistance is increasing in urban
Vietnam, indicating the importance and urgency of the implementation
of regular TDR surveillance. Regular viral load testing is recommended
for early diagnosis of the occurrence of drug resistance and is vital
for curbing the secondary transmission of HIV drug resistant strains.
A gradual scale-up in procurement of second- and higher-line ART
regimens to provide timely treatment for the expanding population of
HIV-infected people with TDR is also essential in reducing the further
spread of drug resistance strains of HIV. Further investigations for
both adults and children are required to provide a more insightful
understanding of the epidemic of drug resistant HIV strains and
identify factors for its control.

References

1. Vietnamese Ministry of Health (2009) Vietnam HIV/AIDS Estimates and
Projections 2007-2012. Accessed August 08, 2011.

2. Vietnam National Committee for AIDS, Drugs, and Prostitution Prevention and
Control (2011) The Fourth Country Report on Following Up the Implementation
To The Declaration of Commitment on HIV and AIDS. Accessed October 20, 2011.

3. Antiretroviral Therapy Cohort Collaboration (2008) Life expectancy of
individuals on combination antiretroviral therapy in high-income countries: a
collaborative analysis of 14 cohort studies. The Lancet 372: 293-299.
23. World Health Organization (2010) Antiretroviral therapy for HIV infection in infants and children: Towards universal access. Recommendations for a public health approach: 2010 revision. Accessed November 10, 2011.
24. Do NT. Preliminary results of the national evaluation of clinical and immunological response to ARV of adult patients in Vietnam. In 4th National Scientific Conference on HIV/AIDS; December 1-3, 2010; Ha Noi, Vietnam.
25. Giang LT, Thuy HT, Nhung VT, Liem NT, Khanh TH, et al. (2008) ARV resistance in patients with treatment failure to first-line regimens in Ho Chi Minh city, Vietnam [Abstract TUPDA201] in XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico AIDS 2008 Accessed August 20, 2011.
26. Nguyenvovan K, Le HT, Quoc TD, Tran CN, Vo QM (2008) HIV drug resistance among patients failing HAART at Tropical Diseases Hospital, Ho Chi Minh city, Vietnam. : AIDS 2008 - XVII International AIDS Conference: Abstract no. CDB0063 Accessed October 1, 2011.
27. Nguyenvovan K, Thi HL, Thi ND, Vinh TL, Thu TH (2008) Viral loads and HIV drug resistance (HIVDR) patterns in ART patients with clinical or immunological failures at outpatient clinics in Ho Chi Minh City, Vietnam [Abstract MOPE040]. In XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico AIDS 2008 Accessed August 20, 2011.
28. Nhung V, Colby D, Khanh T, Viet T, Lu D, Thy H, et al. (2010) HIV drug resistance in children with treatment failure to first-line regimens in Ho Chi Minh City, Vietnam. Journal of the International AIDS Society 13: P140.
29. Truong LXT, Tran TKH, Luong TT, Tran TC, Le TC, Drug resistance among HIV-1 infected patients in Vietnam: The ANRS 12134 study. AIDS Res Hum Retroviruses 25: 1193-1196.
30. Vu T, Le T, Török E, Nguyen Y, Tran C, et al. (2011) HIV-1 Drug Resistance in Antiretroviral-naïve Patients with HIV-associated Tuberculous Meningitis in Ho Chi Minh City, Vietnam [Abstract A629]. In: 16th Conference on Retroviruses and Opportunistic Infections, February 27- March 2, 2011; Boston, United States of America CROI 2011 Accessed August 31, 2011.
31. Phan TTC, Ishizaki A, Phung DC, Bi X, Oka S, et al. (2011) Characterization of HIV Type 1 Genotypes and Drug Resistance Mutations in Antiretroviral-Treatment–Experienced Patients in Vietnam: The ANRS 12134 study. AIDS Res Hum Retroviruses 26: 233-235.
32. Bontelli I, Cuong DA, Agneskos E, Diwan V, Larsson M, et al. (2011) Transmitted drug resistance and phylogenetic analysis of HIV CRF01_AE in Northern Vietnam. AIDS Res Hum Retroviruses 27: 797-801.
33. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D (2008) World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 13: 15-23.
34. Tang AM, Sheehan HB, Jordan MR, Duong DV, Terrin N, et al. (2011) Predictors

Citation: Pham QD, Wilson DP, Zhang L (2012) A Review of the Extent of HIV Drug Resistance in Vietnam. J AIDS Clinic Res 55:001. doi:10.4172/2155-6113.S5-001
of Weight Change in Male HIV-Positive Injection Drug Users Initiating Antiretroviral Therapy in Hanoi, Vietnam. AIDS Res Treat 2011 Epub 2011 Jul 6.

43. Do HM, Dunne MP, Pharm CV, Kato M (2010) Non-adherence to antiretroviral therapy in Vietnam: prevalence and clinical, social and psychological correlates. : Abstract no. TUPDX103 Accessed November 5, 2011.

44. Trinh TT, Montague BT, Flanigan TP, Gerard HM (2011) HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City. AIDS Res Treat Epub 2011 Feb 7.

45. Seyler C, Adje-Toure C, Messou E, Dakoury-Dogbo N, Rouet F, et al. (2007) Impact of genotypic drug resistance mutations on clinical and immunological outcomes in HIV-infected adults on HAART in West Africa. AIDS 21:1157-1164.

46. Verhoffstede C, Van Warzeele F, Van Der Gucht B, Pelgrom J, Van dekerckhove L, et al. (2007) Detection of drug resistance mutations as a predictor of subsequent virological failure in patients on ART-1 viral rebounds of less than 1,000 RNA copies/ml. J Med Virol 79: 1254-1260.

47. Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, et al. (2005) Detection and quantification of proviral HIV-1 184MV in circulating CD4+ T cells of patients on HAART with a viremia less than 1000 copies/ml. J Clin Virol: the official publication of the Pan American Society for Clinical Virology 34: 257-267.

48. Bangsberg DR, Charlebois ED, Grant RM, Holodniy M, Deeks SG, et al. (2003) High levels of adherence do not prevent accumulation of HIV drug resistance mutations. AIDS 17: 1925-1932.

49. Bangsberg DR, Moss AR, Deeks SG (2004) Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 53: 696-699.

50. Gardner EM, Burman JW, Steiner JF, Anderson PL, Bangsberg DR (2009) Antiretroviral medication adherence and the development of class-specific antiretroviral resistance. AIDS 23: 1035-1046.

51. Tam LWY, Chu CKS, Brumme CJ, Bangsberg DR, Montaner JSG, et al. (2008) The Relationship Between Resistance and Adherence in Drug-Naive Individuals Initiating HAART Is Specific to Individual Drug Classes. J Acquir Immune Defic Syndr 49: 266-271.

52. Lima VC, Harrigan R, Murray M, Moore DM, Wood E, et al. (2008) Differential impact of adherence on long-term treatment response among naïve HIV-infected individuals. AIDS 22: 2371-2380.

53. Gardner EM, Hullsiek KH, Telzak EE, Shama S, Peng G, et al. (2010) Antiretroviral medication adherence and class-specific resistance in a large prospective clinical trial. AIDS 24: 395-403.

54. Van Tam V, Pharris A, Thorson A, Alffen T, Larsson M (2011) “It is not that I forget, it’s just that I don’t want other people to know”: barriers to and strategies for adherence to antiretroviral therapy among HIV patients in Northern Vietnam. AIDS Care 23: 139-145.

55. Phillips AN, Pillay D, Garnett G, Bennett D, Vitoria M, et al. (2011) Effect on transmission of HIV-1 resistance of timing of implementation of viral load monitoring to determine switches from first to second-line antiretroviral regimens in resource-limited settings. AIDS 25: 843-850.

56. Hoare A, Kerr SJ, Ruxunghnam K, Anawarornich J, Law MG, et al. (2010) Hidden Drug Resistant HIV to emerge in the Era of Universal Treatment Access in Southeast Asia. PLoS One 5: e10981.

57. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO (2001) Predicting the unpredictable: Transmission of drug-resistant HIV. Nat Med 7: 1016-1020.

58. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S (2010) Evolutionary Dynamics of Complex Networks of HIV Drug-Resistant Strains: The Case of San Francisco. Science 327: 697-701.

59. Vardavas R, Blower S (2007) The emergence of HIV transmitted resistance in Botswana: “When will the WHO detection threshold be exceeded?”. PLoS One 2: e152.

60. Liao L, Xing H, Shang H, Li J, Zhong P, et al. (2010) The prevalence of transmitted antiretroviral drug resistance in treatment-naive HIV-infected individuals in China. J Acquir Immune Defic Syndr 53: S10-S14.

61. Li JZ, Paredes R, Ribaudo HJ, Svarovskaia ES, Metzner KJ, et al. (2011) Low-Frequency HIV-1 Drug Resistance Mutations and Risk of NNRTI-Based Antiretroviral Treatment Failure. JAMA 305: 1327-1335.

62. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, et al. (2011) Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 11: 363-371.

63. Tran T, Vu TX, Luong AQ, Truong LXT. Early Infant Diagnosis for Children under 18 Months of Age Born to HIV Positive Mother in the Southern Vietnam. In 4th National Scientific Conference on HIV/AIDS; December 1-3, 2010; Ha Noi, Vietnam. 2010.

64. Green H, Titlton P, Fearnhill E, Pillay D, Dunn DT (2008) The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom. J Acquir Immune Defic Syndr 49: 196-204.

65. Jain V, Sucupira MC, Bacchetti P, Hartogensis W, Diaz RS, et al. (2011) Differential Persistence of Transmitted HIV-1 Drug Resistance Mutation Classes. J Infect Dis 203: 1174-1181.

66. Schuurman R, Demeter L, Reichelderfer P, Tijngel J, de Groof T, et al. (1999) Worldwide Evaluation of DNA Sequencing Approaches for Identification of Resistance Mutation in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase. J Clin Microbiol 37: 2291-2296.

67. Lan NTH, Recordon-Pinson P, Hung PV, Uyen NTV, Lien TTX, et al. (2003) HIV Type 1 Isolates from 200 Untreated Individuals in Ho Chi Minh City (Vietnam): ANRS 1257 Study. Large Predominance of CRF01_AE and Presence of Major Resistance Mutations to Antiretroviral Drugs. AIDS Res Hum Retroviruses 19: 925-928.

68. Ishizaki A, Cuong NH, Thuc PV, Trung NV, Saijoh K, et al. (2009) Profile of HIV Type 1 Infection and Genotypic Resistance Mutations to Antiretroviral Drugs in Treatment-Naive HIV Type 1-Infected Individuals in Hai Phong, Viet Nam. AIDS Res Hum Retroviruses 25: 175-182.